FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207791950> ?p ?o ?g. }

• W3207791950 abstract "To date, chemotherapy remains the only effective treatment of unresectable pancreatic adenocarcinoma. In the past few years, the interest in immunological anticancer therapy rises sharply. AGIG is a novel chemo-immunotherapy regimen that combines nab-paclitaxel + gemcitabine chemotherapy with sequential recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) therapy. We conducted a single-arm prospective phase II study to determine the efficacy and safety of the first-line treatment of advanced pancreatic cancer with AGIG regimen.Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously to all patients on days 1 and 8 triweekly, interleukin-2 (1000000U) and GM-CSF (100 µg) were administered subcutaneously on days 3-5 after chemotherapy. The primary end point was ORR by the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included safety profile, progression-free survival (PFS), overall survival (OS). Patients' conditions along with the efficacy and safety were assessed every two cycles.Between 11/2018 and 01/2020, sixty-four patients were enrolled. In the sixty-four evaluable patients, the disease control rate (DCR) and overall response rate (ORR) were 76.6% and 43.75%, respectively. The median follow-up time was 12.1 (range 7.1-22.4) months. The median PFS was 5.7 (range 1.63-15.8) months. The median OS was 14.2 (range 2.9-22.0) months. The most common adverse event was fever (75%). The incidence of III/IV grade neutropenia was 4.69%. In subgroup analyses, we found that eosinophil count in the blood elevated three times higher than baseline level predicted a longer survival.The AGIG chemo-immunotherapy regimen has presented favorable ORR, OS, and manageable toxicities as first-line therapeutic strategy of advanced pancreatic cancer treatment. This regimen may be a novel reliable therapeutic option for patients with preserved performance status. The improvement of treatment efficiency may be related to the activation of non-specific immune response.https://clinicaltrials.gov/. identifier NCT03768687." @default.
• W3207791950 created "2021-10-25" @default.
• W3207791950 creator A5004716187 @default.
• W3207791950 creator A5018104991 @default.
• W3207791950 creator A5030659990 @default.
• W3207791950 creator A5031279957 @default.
• W3207791950 creator A5044406679 @default.
• W3207791950 creator A5045364810 @default.
• W3207791950 creator A5059386730 @default.
• W3207791950 creator A5082142551 @default.
• W3207791950 date "2021-10-13" @default.
• W3207791950 modified "2023-10-16" @default.
• W3207791950 title "AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study" @default.
• W3207791950 cites W1860439073 @default.
• W3207791950 cites W1912735458 @default.
• W3207791950 cites W1955188776 @default.
• W3207791950 cites W1976171528 @default.
• W3207791950 cites W1993151948 @default.
• W3207791950 cites W2041389044 @default.
• W3207791950 cites W2056849373 @default.
• W3207791950 cites W2060094878 @default.
• W3207791950 cites W2115658806 @default.
• W3207791950 cites W2136866696 @default.
• W3207791950 cites W2154981835 @default.
• W3207791950 cites W2165480504 @default.
• W3207791950 cites W2413313789 @default.
• W3207791950 cites W2595367519 @default.
• W3207791950 cites W2649656222 @default.
• W3207791950 cites W2735949777 @default.
• W3207791950 cites W2746094882 @default.
• W3207791950 cites W2751701466 @default.
• W3207791950 cites W2765823162 @default.
• W3207791950 cites W2772923107 @default.
• W3207791950 cites W2777989556 @default.
• W3207791950 cites W2796317885 @default.
• W3207791950 cites W2836222598 @default.
• W3207791950 cites W2887205254 @default.
• W3207791950 cites W2889710175 @default.
• W3207791950 cites W2890610945 @default.
• W3207791950 cites W2901590302 @default.
• W3207791950 cites W2909997346 @default.
• W3207791950 cites W2945579431 @default.
• W3207791950 cites W2947955936 @default.
• W3207791950 cites W2968732658 @default.
• W3207791950 cites W2981739628 @default.
• W3207791950 cites W3000487074 @default.
• W3207791950 cites W3043025818 @default.
• W3207791950 cites W3096943432 @default.
• W3207791950 doi "https://doi.org/10.3389/fonc.2021.693386" @default.
• W3207791950 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8548663" @default.
• W3207791950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34722242" @default.
• W3207791950 hasPublicationYear "2021" @default.
• W3207791950 type Work @default.
• W3207791950 sameAs 3207791950 @default.
• W3207791950 citedByCount "0" @default.
• W3207791950 crossrefType "journal-article" @default.
• W3207791950 hasAuthorship W3207791950A5004716187 @default.
• W3207791950 hasAuthorship W3207791950A5018104991 @default.
• W3207791950 hasAuthorship W3207791950A5030659990 @default.
• W3207791950 hasAuthorship W3207791950A5031279957 @default.
• W3207791950 hasAuthorship W3207791950A5044406679 @default.
• W3207791950 hasAuthorship W3207791950A5045364810 @default.
• W3207791950 hasAuthorship W3207791950A5059386730 @default.
• W3207791950 hasAuthorship W3207791950A5082142551 @default.
• W3207791950 hasBestOaLocation W32077919501 @default.
• W3207791950 hasConcept C121608353 @default.
• W3207791950 hasConcept C126322002 @default.
• W3207791950 hasConcept C141071460 @default.
• W3207791950 hasConcept C143998085 @default.
• W3207791950 hasConcept C197934379 @default.
• W3207791950 hasConcept C203092338 @default.
• W3207791950 hasConcept C2776694085 @default.
• W3207791950 hasConcept C2777063308 @default.
• W3207791950 hasConcept C2777701055 @default.
• W3207791950 hasConcept C2778336483 @default.
• W3207791950 hasConcept C2780210213 @default.
• W3207791950 hasConcept C2780258809 @default.
• W3207791950 hasConcept C2781413609 @default.
• W3207791950 hasConcept C31760486 @default.
• W3207791950 hasConcept C535046627 @default.
• W3207791950 hasConcept C71924100 @default.
• W3207791950 hasConcept C90924648 @default.
• W3207791950 hasConceptScore W3207791950C121608353 @default.
• W3207791950 hasConceptScore W3207791950C126322002 @default.
• W3207791950 hasConceptScore W3207791950C141071460 @default.
• W3207791950 hasConceptScore W3207791950C143998085 @default.
• W3207791950 hasConceptScore W3207791950C197934379 @default.
• W3207791950 hasConceptScore W3207791950C203092338 @default.
• W3207791950 hasConceptScore W3207791950C2776694085 @default.
• W3207791950 hasConceptScore W3207791950C2777063308 @default.
• W3207791950 hasConceptScore W3207791950C2777701055 @default.
• W3207791950 hasConceptScore W3207791950C2778336483 @default.
• W3207791950 hasConceptScore W3207791950C2780210213 @default.
• W3207791950 hasConceptScore W3207791950C2780258809 @default.
• W3207791950 hasConceptScore W3207791950C2781413609 @default.
• W3207791950 hasConceptScore W3207791950C31760486 @default.
• W3207791950 hasConceptScore W3207791950C535046627 @default.
• W3207791950 hasConceptScore W3207791950C71924100 @default.
• W3207791950 hasConceptScore W3207791950C90924648 @default.
• W3207791950 hasLocation W32077919501 @default.

• next